Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma

Neuro-Oncology

Volumn 8, Issue 2, 2006, Pages 89-95

  Freeman III, Burgess B ^a   Iacono, Lisa C ^a   Panetta, John C ^a,b   Gajjar, Amar ^a,c   Stewart, Clinton F ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Cerebrospinal fluid; Children; Pharmacokinetics; Topotecan

Indexed keywords

TOPOTECAN; ANTINEOPLASTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID FLOW; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; FEMALE; HUMAN; MALE; MEDULLOBLASTOMA; ADOLESCENT; ADULT; BIOLOGICAL MODEL; BLOOD; CEREBELLUM TUMOR; CLINICAL TRIAL; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MEDULLOBLASTOMA; MODELS, BIOLOGICAL; TOPOTECAN;

EID: 33744492870     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2005-004     Document Type: Article

References (16)

1. Baker, S.D., Heideman, R.L., Crom, W.R., Kuttesch, J.F., Gajjar, A., and Stewart, C.F. (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous System tumors. Cancer Chemother. Pharmacol. 37, 195-202.
2. Blaney, S.M., Cole, D.E., Balis, F.M., Godwin, K., and Poplack, D.G. (1993) Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 53, 725-727.
3. D'Argenio, D.Z., and Schumitzky, A. (1990) ADAPT II User's Guide, 1st ed. Los Angeles: Biomedical Simulations Resource, University of Southern California.
4. Ellison, D.W., Clifford, S.C., Gajjar, A., and Gilbertson, R.J. (2003) What's new in neuro-oncology? Recent advances in medulloblastoma. Eur. J. Paediatr. Neurol. 7, 53-66.
5. Gajjar, AJ., Kirstein, M.N., Santana, V.M., Furman, W.L., Thompson, S., Houghton, P.J., and Stewart, C.F. (2001) Concomitant dexamethasone (DXM) increases topotecan (TPT) clearance in children. Proc. Am. Assoc. Cancer. Res. 42, 653 (abstract).
6. Gibaldi, M., and Perrier, D. (1982) Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
7. Lishner, M., Perrin, R.G., Feld, R., Messner, H.A., Tuffnell, P.C., Elhakim, T., Matlow, A., and Curtis, J.E. (1990) Complications associated with Ommaya reservoirs in patients with cancer. The Princess Margaret Hospital experience and a review of the literature. Arch. Intern. Med. 150, 173-176.
8. Pawlik, C.A., Houghton, PJ., Stewart, C.F., Cheshire, P.J., Richmond, L.B., and Danks, M.K. (1998) Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin. Cancer Res. 4, 1995-2002.
9. Pratt, C.B., Stewart, C.F., Santana, V.M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J.F., Heideman, R., Sandlund, J.T., Avery, L., and Meyer, W.H. (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol. 12, 539-543.
10. Santana, V.M., Zamboni, W.C., Kirstein, M.N., Tan, M., Liu, T., Gajjar A, Houghton, P.J., and Stewart, C.F. (2003) A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin. Cancer Res. 9, 633-640.
11. Steimer, J.-L., Ebelin, M.-E., and Van Bree, J. (1993) Pharmacokinetic and pharmacodynamic data and models in clinical trials, Eur. J. Drug Metab. Pharmacokinet. 18, 61-76.
12. Stewart, C.F., Liu, C.Y., Zamboni, W.C., Ma, M.K., Kirstein, M.N., Hanna, S.K., Gajjar, A.J., Santana, V.M., Houghton, P.J., and Sambol, N.C. (2000) Population pharmacokinetics of topotecan in children and adolescents. Proc. Am. Soc. Clin. Oncol. 19, 177a (abstract 687).
13. Stewart, C.F., Iacono, L.C., Chintagumpala, M., Kellie, S.J., Ashley, D., Zamboni, W.C., Kirstein, M., Fouladi, M., Seele, L.G., Wallace, D., Houghton, P.J., and Gajjar, A. (2004) Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J. Clin. Oncol. 22, 3357-3365.
14. Tubergen, D.G., Stewart, C.F., Pratt, C.B., Zamboni, W.C., Winick, N., Santana, V.M., Dryer, Z.A., Kurtzberg, J., Bell, B., Grier, H., and Vietti, T.J. (1996) Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol. 18, 352-361.
15. Zamboni, W.C., Stewart, C.F., Thompson, J., Santana, V.M., Cheshire, P.J., Richmond, L.B., Luo, X., Poquette, C., Houghton, J.A., and Houghton, P.J. (1998a) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst. 90, 505-511.
16. Zamboni, W.C., Gajjar, A.J., Heideman, R.L., Beijnen, J.H., Rosing, H., Houghton, P.J., and Stewart, C.F. (1998b) Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin. Cancer Res. 4, 783-789.